Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
20
02
2020
revised:
28
04
2020
accepted:
30
04
2020
pubmed:
30
5
2020
medline:
30
5
2020
entrez:
30
5
2020
Statut:
ppublish
Résumé
BRAFV600-mutated colorectal cancer (CRC) accounts for 8% to 12% of all CRC diagnoses. These tumors are often associated with specific patient features, including right-sided primary tumor location, peritoneal and non-regional lymph node involvement, and poor prognosis. In approximately 30% of cases, a simultaneous mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) phenotype is identified. The prognostic impact of the BRAF mutation appears to be less marked in patients with MSI-H CRC than in patients with microsatellite stable (MSS) tumor. The treatment of BRAFV600-mutated CRC is still a challenge for the clinicians, mainly due to the poor survival outcomes obtained with traditional chemotherapy regimens. In recent years, two novel treatment strategies have offered remarkable changes in the treatment of this specific patient subgroup. The first approach has included targeted therapies directed against BRAF and MEK, with support from the epidermal growth factor receptor (EGFR) blockade. The second approach has included immunotherapeutic agents that have been shown to be particularly promising for patients with simultaneous dMMR/MSI-H phenotype. Here we review the clinical trials that specifically enrolled patients with BRAF-mutated CRC, from the phase I/II studies to the phase III trial BEACON CRC. We also examine the future directions towards a molecularly guided therapy for patients with BRAF-mutated CRC and the crucial role of a molecularly and clinically based algorithm in order to offer the best choice of treatment for these patients.
Identifiants
pubmed: 32470910
pii: S1936-5233(20)30205-9
doi: 10.1016/j.tranon.2020.100795
pmc: PMC7260582
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100795Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that there are no conflicts of interest.
Références
Clin Cancer Res. 2014 Oct 15;20(20):5322-30
pubmed: 25139339
N Engl J Med. 2008 Oct 23;359(17):1757-65
pubmed: 18946061
J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24
pubmed: 19738166
Ann Oncol. 2015 Jan;26(1):13-21
pubmed: 25115304
Cancer Discov. 2018 Apr;8(4):428-443
pubmed: 29431699
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Clin Oncol. 1997 Mar;15(3):938-46
pubmed: 9060531
Lancet Oncol. 2018 May;19(5):603-615
pubmed: 29573941
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Mol Cancer Res. 2007 Mar;5(3):203-20
pubmed: 17374728
J Clin Oncol. 2017 Aug 10;35(23):2624-2630
pubmed: 28486044
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
Eur J Cancer. 2015 Mar;51(5):587-94
pubmed: 25673558
Nature. 2012 Jan 26;483(7387):100-3
pubmed: 22281684
Cancer Discov. 2016 Dec;6(12):1352-1365
pubmed: 27729313
J Clin Oncol. 2015 Dec 1;33(34):4032-8
pubmed: 26460303
Cancer. 1986 May 1;57(9):1866-70
pubmed: 3485470
Cancer. 2011 Oct 15;117(20):4623-32
pubmed: 21456008
Lancet Oncol. 2015 Oct;16(13):1306-15
pubmed: 26338525
Cancer Lett. 2009 Oct 8;283(2):125-34
pubmed: 19217204
Clin Cancer Res. 2015 Mar 15;21(6):1313-20
pubmed: 25589621
N Engl J Med. 2019 Oct 24;381(17):1632-1643
pubmed: 31566309
J Clin Oncol. 2021 Feb 1;39(4):285-294
pubmed: 33356422
Arch Surg. 2000 May;135(5):530-4; discussion 534-5
pubmed: 10807276
J Clin Oncol. 2020 Jan 1;38(1):11-19
pubmed: 31725351
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Lancet Oncol. 2011 Jun;12(6):594-603
pubmed: 21163703
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
J Clin Oncol. 2015 Dec 1;33(34):4023-31
pubmed: 26392102
Cancer Cell. 2012 Nov 13;22(5):668-82
pubmed: 23153539
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Cancer Discov. 2012 Mar;2(3):227-35
pubmed: 22448344
Eur J Cancer. 2019 Sep;118:121-130
pubmed: 31330487
J Clin Oncol. 2011 Apr 1;29(10):1261-70
pubmed: 21383284
J Natl Cancer Inst. 2016 Dec 31;109(5):
pubmed: 28040692
Br J Cancer. 2015 Jun 9;112(12):1888-94
pubmed: 25989278
Cancer Discov. 2017 Jun;7(6):610-619
pubmed: 28363909